日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

PRL3-zumab as an anti-angiogenic therapy in neovascular eye diseases.

PRL3-zumab 作为新生血管性眼病的抗血管生成疗法

Ang Koon Hwee, Thura Min, Tan Queenie Shu Woon, Gupta Abhishek, Kuan Kam Yew, Li Jie, Chia Pei Ling, Qiu Beiying, Hong Jimmy Ming, Guo Ke, Wang Xiaomeng, Su Xinyi, Zeng Qi

The PRL3-zumab paradigm: A multicenter, single-dose-level phase 2 basket clinical trial design of an unconventional cancer immunotherapy

PRL3-zumab 范式:一项非常规癌症免疫疗法的多中心、单剂量水平 II 期篮式临床试验设计

Park, David J; Thura, Min; Chiu, Vi K; Vicuna, Brian; Ang, Koon Hwee; Sanchez, Blanca; Chia, Pei Ling; Kuan, Kam Yew; Li, Jie; Zhang, Ke; Zheng, Wei Hui; Hsien Ng, Matthew Chau; Zeng, Qi

PRL3 as a therapeutic target for novel cancer immunotherapy in multiple cancer types

PRL3作为多种癌症类型新型癌症免疫疗法的治疗靶点

Chia, Pei Ling; Ang, Koon Hwee; Thura, Min; Zeng, Qi